Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Crossbow Therapeutics Inc.
Headquarters: Cambridge, MA, United States of America
Website: https://www.crossbowtx.com
Year Founded: 2021
Status: Private
See Emerging Company Profile .
BioCentury | Oct 22, 2024
Product Development
Newco trend watch: Clusters of launches point to areas undergoing derisking
Oligo delivery to the kidney, and two emerging use cases for T cell engagers, each get newcos; most with mega-
BioCentury | Jul 18, 2024
Emerging Company Profile
Clasp: Optimizing T cell engagers for tighter binding, more cancer killing
Launched in March with $150M, Clasp is designing T cell-engaging bispecifics to better fit the immune synapse
BioCentury | May 21, 2024
Emerging Company Profile
Crossbow: Tumor antigen targeting beyond cell surface proteins, at scale
Through antibody targeting of HLA-peptide complexes, the MPM-built biotech is turning intracellular tumor antigens into handles for T cell engagers
BioCentury | Jul 12, 2023
Deals
July 11 Quick Takes: Novartis, BeiGene end TIGIT deal
Plus: MPM’s Crossbow debuts with $80M series A and updates from Septerna, ADC, Kelun-Biotech, Evotec and more
Items per page:
1 - 4 of 4